Advancing mRNA-based cell therapies: the crucial role of mRNA optimization for therapeutic efficacy

Christian Bär, Ulrich Blache, Sandy Tretbar

23 January 2025

Viewpoint

Bio-printing in the context of end-to-end scalable tissue-engineered ATMP manufacturing

Isaak Decoene, Ioannis Papantoniou

12 December 2024

Viewpoint

Industrializing cell therapy: how to bring curative therapies to all patients who need them?

Jens Vogel

20 November 2024

Viewpoint

Decentralizing gene and cell therapy manufacturing: changing tides or uphill battle

Magdi Elsallab

04 October 2024

Viewpoint

A pathway forward for CAR-NK cell therapy

Scott McComb

06 August 2024

Viewpoint

Enabling affordable access to CAR-T cell and other cellular gene therapy products

R Orentas, Y Xiong, I Oparaocha et al

13 May 2024

Viewpoint

Autologous induced pluripotent stem cell (iPSC)-derived therapies: a realistic solution for advancing regenerative medicine

Jarett Anderson, Timothy Nelson

17 January 2024

Viewpoint

Following the (mAb) leader: leveraging monoclonal antibody cell line development & banking CMC strategies for iPSC-derived cell therapies

Damien Fink

17 January 2024

Viewpoint

Scale-up and automation of iPSC-derived cell therapy manufacturing

Dhruv Sareen, Jonathan Rodriguez, Hojae Lee

05 October 2023

Viewpoint

Standardizing success: paving the way for streamlined viral vector manufacturing in gene therapy

Raquel Martín-Ibáñez

26 April 2023

Viewpoint

Setting up a one-stop shop: bringing viral vector manufacturing in-house

Danielle Steele

17 April 2023

Viewpoint

Transfection optimization for AAV production

Peter Boyce

03 April 2023

Viewpoint

Distributed manufacturing models for ATMPs: can they work: do we understand the pitfalls?

Mark Lowdell

02 March 2023

Viewpoint

Current trends in advanced therapy development & commercialization for rare diseases

Alan Boyd

28 February 2023

Viewpoint

Key considerations for early investment in the process development of cell-based therapeutics

Kelly Kemp, Sebastian Rieck

23 November 2022

Viewpoint

Building resilience into post-pandemic cell & gene therapy supply chains

Tiffany Clement, Cheryl Cox

18 November 2022

Viewpoint

The living cell supply chain: a product-specific, rational approach to management of cellular starting material donors & donations

William E Janssen, Scott R. Burger

18 November 2022

Viewpoint

Producing cell-based therapeutic products with lot-to-lot consistency from highly variable starting cell products

William E Janssen, Scott R Burger

02 November 2022

Viewpoint

Future trends in viral vector process & product development

Ramji Krishnan

28 April 2022

Viewpoint

Pandemic-related supply chain disruptions in cell therapy require rapid qualification for single-sourced materials

John Duguid, Paul Friedman

07 March 2022

Viewpoint

Process analytical technology tools for process monitoring in CGT product manufacturing

Wai Lam W Ling, Arun C Patel

18 January 2022

Viewpoint